List of Excipients in Branded Drug MIFEPRISTONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Corcept Therapeutics Incorporated	MIFEPRISTONE	mifepristone	76346-654	ALUMINUM OXIDE
Corcept Therapeutics Incorporated	MIFEPRISTONE	mifepristone	76346-654	CELLULOSE, MICROCRYSTALLINE
Corcept Therapeutics Incorporated	MIFEPRISTONE	mifepristone	76346-654	D&C YELLOW NO. 10
Corcept Therapeutics Incorporated	MIFEPRISTONE	mifepristone	76346-654	FD&C YELLOW NO. 6
Corcept Therapeutics Incorporated	MIFEPRISTONE	mifepristone	76346-654	HYDROXYPROPYL CELLULOSE

Generic Drugs Containing MIFEPRISTONE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	mifepristone	0591-4390	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	mifepristone	0591-4390	FD&C BLUE NO. 1
Actavis Pharma Inc	mifepristone	0591-4390	FD&C YELLOW NO. 5 ALUMINUM LAKE
Actavis Pharma Inc	mifepristone	0591-4390	FD&C YELLOW NO. 6
Actavis Pharma Inc	mifepristone	0591-4390	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in MIFEPRISTONE?

# Of NDCs	Excipient
3	CELLULOSE, MICROCRYSTALLINE
1	FD&C BLUE NO. 1
1	FD&C YELLOW NO. 5 ALUMINUM LAKE
1	FD&C YELLOW NO. 6
1	HYDROXYPROPYL CELLULOSE

Excipient Strategy and Commercial Opportunities for Mifepristone

Last updated: February 25, 2026

What are the key excipient considerations for Mifepristone formulation?

Mifepristone's formulation relies on excipients that ensure stability, bioavailability, and patient safety. Its oral form requires excipients that facilitate solubility and absorption. Common excipients include lactose monohydrate, microcrystalline cellulose, and magnesium stearate in tablet formulations. Its high lipophilicity necessitates the inclusion of disintegrants and surfactants to improve dissolution.

Stability issues relate to hydrolysis and oxidation, prompting the use of antioxidants like tocopherols or ascorbic acid. For variations such as vaginal tablets or capsules, excipients like polyethylene glycol, gel-forming agents, or gelatin may be employed to optimize application or release profiles.

How does excipient selection impact patentability and formulation exclusivity?

Unique excipient combinations or innovative delivery systems can extend patent life and market exclusivity. For example, developing controlled-release formulations with novel excipients can differentiate products. Patent strategies often include novel excipient mixtures or encapsulation techniques that improve stability or reduce side effects.

Compounds that improve bioavailability—like lipid-based excipients—may allow patenting of delivery methods or formulations. Regulatory agencies scrutinize excipients for safety, but inventive combinations with proven safety profiles can create proprietary advantages.

What are the commercial opportunities linked to excipient innovations for Mifepristone?

Opportunities exist in developing new formulations, such as sustained-release tablets or alternative delivery systems, to expand clinical applications or improve patient compliance. Patent filings for such innovations can create barriers to entry for competitors.

Market growth can be driven by expanding indications in conditions like Cushing's syndrome and potential new uses. Enhanced formulations offering improved efficacy, fewer side effects, or patient-friendly dosage forms can command premium pricing.

Generic manufacturers may seek to develop bioequivalent formulations utilizing alternative excipients, reducing development costs. Partnerships with excipient manufacturers can facilitate innovation, improve supply chain resilience, and reduce costs.

What regulatory and safety considerations influence excipient strategy?

Regulatory approval depends on excipient safety, particularly for reproductive-age women and pregnant patients. Excipients with known allergenic or toxic potential are limited. Regulatory pathways favor excipients with established safety profiles, which can narrow options but streamline approval.

Variability in excipient quality can impact manufacturing consistency and regulatory compliance. Conducting thorough stability, compatibility, and toxicology testing for new excipients is essential before commercialization.

How can excipient strategy drive competitive advantage in Mifepristone's market?

Differentiating through innovative excipient use can improve clinical outcomes and patient adherence. Patent protection for formulation innovations prevents direct competition. Global supply chain management of key excipients ensures reliable production.

Collaboration with excipient suppliers to develop high-purity, compliant materials can reduce regulatory hurdles and manufacturing delays. Evolving patient preferences for oral, less frequent, or combination formulations open new market segments.

Key Takeaways

• Excipient choice impacts stability, bioavailability, and regulatory approval for Mifepristone formulations.
• Innovation in excipient combinations or delivery methods extends product patent life.
• Developing alternative formulations—such as sustained-release or novel delivery systems—offers market expansion and premium pricing opportunities.
• Regulatory and safety considerations limit excipient options; thorough testing and compliance are mandatory.
• Supply chain control and collaborative innovation provide competitive advantages.

FAQs

1. What excipients are commonly used in Mifepristone tablets?
Lactose monohydrate, microcrystalline cellulose, magnesium stearate, and disintegrants like croscarmellose sodium.

2. How can excipient innovation extend patent protection?
By creating novel formulations, delivery systems, or excipient combinations that are patentable, companies can prolong market exclusivity.

3. Are there safety concerns with excipients in reproductive health medications?
Yes. Safety profiles must be thoroughly evaluated, especially for excipients that could cause allergic reactions or toxicity.

4. What role do excipients play in developing generic versions of Mifepristone?
Excipients affect bioequivalence and stability; choosing cost-effective, approved excipients facilitates generic development.

5. How do regulatory agencies influence excipient selection for Mifepristone?
They favor excipients with well-established safety profiles and require comprehensive testing for new excipients.

---

References

1. U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Approved Drug Products.
2. International Conference on Harmonisation. (2009). ICH Q3C(R6): Guideline for Residual Solvents.
3. World Health Organization. (2017). WHO Model Formulary 2017.
4. European Medicines Agency. (2021). Reflection paper on excipients in biopharmaceuticals.
5. Gans, R. (2021). Innovative formulation strategies for improved drug delivery. Pharmaceutics, 13(5), 769.